Meeder Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-51
| Closed | -$3K | – | 1454 |
|
|
2022
Q3 | $3K | Buy |
51
+9
| +21% | +$529 | ﹤0.01% | 1721 |
|
|
2022
Q2 | $2K | Buy |
42
+29
| +223% | +$1.38K | ﹤0.01% | 1898 |
|
|
2022
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 2202 |
|
|
2021
Q4 | $1K | Sell |
13
-397
| -97% | -$30.5K | ﹤0.01% | 1029 |
|
|
2021
Q3 | $35K | Buy |
410
+73
| +22% | +$6.23K | ﹤0.01% | 1206 |
|
|
2021
Q2 | $27K | Buy |
337
+148
| +78% | +$11.9K | ﹤0.01% | 1355 |
|
|
2021
Q1 | $18K | Buy |
189
+58
| +44% | +$5.52K | ﹤0.01% | 1440 |
|
|
2020
Q4 | $8K | Sell |
131
-5,556
| -98% | -$339K | ﹤0.01% | 1061 |
|
|
2020
Q3 | $338K | Buy |
5,687
+428
| +8% | +$25.4K | 0.02% | 476 |
|
|
2020
Q2 | $367K | Sell |
5,259
-4,673
| -47% | -$326K | 0.02% | 448 |
|
|
2020
Q1 | $450K | Buy |
+9,932
| New | +$450K | 0.04% | 356 |
|
|
2018
Q4 | – | Sell |
-298
| Closed | -$51K | – | 1758 |
|
|
2018
Q3 | $51K | Buy |
298
+118
| +66% | +$20.2K | ﹤0.01% | 776 |
|
|
2018
Q2 | $23.2K | Buy |
+180
| New | +$23.2K | ﹤0.01% | 931 |
|
|
2018
Q1 | – | Sell |
-51
| Closed | -$4K | – | 1654 |
|
|
2017
Q4 | $4K | Buy |
51
+6
| +13% | +$471 | ﹤0.01% | 1364 |
|
|
2017
Q3 | $4K | Buy |
+45
| New | +$4K | ﹤0.01% | 1323 |
|
|
2016
Q3 | – | Sell |
-2,403
| Closed | -$179K | – | 856 |
|
|
2016
Q2 | $179K | Buy |
+2,403
| New | +$179K | 0.02% | 582 |
|